Age, years
Range (mean ± SD)
|
39-85 (65.5 ± 10.3)
|
Sex
Male
Female
|
24 (57.1)
18 (42.9)
|
Underlying malignancy
Cutaneous
Melanoma
Merkel cell carcinoma
Cutaneous SCC of head and neck
Sebaceous carcinoma
Lung
Sq NSCLC
Non-Sq NSCLC
Gastrointestinal
Esophageal SCC
Gastric adenocarcinoma
Genitourinary
Renal cell carcinoma
Urothelial carcinoma
|
17 (40.5)
12 (28.6)
1 (2.4)
3 (7.1)
1 (2.4)
17 (40.5)
7 (16.7)
10 (23.8)
3 (7.1)
2 (4.8)
1 (2.4)
5 (11.9)
4 (9.5)
1 (2.4)
|
Immune checkpoint inhibitors
Nivolumab
Pembrolizumab
Ipilimumab
Nivolumab + ipilimumab
Atezolizumab
Avelumab
|
18 (45.0)
10 (25.0)
2 (5.0)
5 (12.5)
3 (7.5)
2 (5.0)
|
Total |
40 (100.0) |